The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| G03GA08 | Choriogonadotropin alfa | G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| OVIDREL Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
| OVITRELLE Solution for injection in pre-filled syringe | European Medicines Agency (EU) | MPI, EU: SmPC |
Choriogonadotropin alpha is an active ingredient of these brands:
United States (US)Australia (AU)Austria (AT)
Brazil (BR)Canada (CA)Croatia (HR)
Cyprus (CY)
Ecuador (EC)Estonia (EE)
Finland (FI)
France (FR)
Hong Kong (HK)Ireland (IE)
Israel (IL)
Italy (IT)
Japan (JP)Lithuania (LT)
Netherlands (NL)
New Zealand (NZ)Poland (PL)
Romania (RO)
Singapore (SG)Spain (ES)
Tunisia (TN)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
